Harshani R Lawrence

Harshani R Lawrence

UNVERIFIED PROFILE

Are you Harshani R Lawrence?   Register this Author

Register author
Harshani R Lawrence

Harshani R Lawrence

Publications by authors named "Harshani R Lawrence"

Are you Harshani R Lawrence?   Register this Author

41Publications

-Reads

Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition.

Mol Oncol 2018 Jan 23;12(1):74-88. Epub 2017 Nov 23.

The Department of Tumor Biology, The Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

View Article
January 2018

Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells.

Sci Rep 2018 Jan 31;8(1):1954. Epub 2018 Jan 31.

Tumor Biology Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA.

View Article
January 2018

Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.

ACS Chem Biol 2017 07 7;12(7):1883-1892. Epub 2017 Jun 7.

Drug Discovery Department, H. Lee Moffitt Cancer Center & Research Institute , Tampa, Florida 33612, United States.

View Article
July 2017

ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer.

Cancer Cell 2017 06;31(6):790-803.e8

Drug Discovery Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA; Department of Oncological Sciences, University of South Florida, Tampa, FL 33612, USA. Electronic address:

View Article
June 2017

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.

Cell Chem Biol 2016 Dec 17;23(12):1490-1503. Epub 2016 Nov 17.

Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

View Article
December 2016

CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.

J Leukoc Biol 2015 Apr 6;97(4):807-19. Epub 2015 Feb 6.

Departments of *Blood and Marrow Transplantation, Immunology, Hematopathology and Laboratory Medicine, Drug Discovery, and Biostatistics, Analytic Microscopy Core, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.

View Article
April 2015

Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.

J Med Chem 2015 Mar 17;58(6):2746-63. Epub 2015 Mar 17.

§Department of Oncologic Sciences, University of South Florida, Tampa, Florida 33620, United States.

View Article
March 2015

ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1.

J Biol Chem 2014 Oct 22;289(41):28179-91. Epub 2014 Aug 22.

From the Drug Discovery Department, Moffitt Cancer Center, and the Department of Oncologic Sciences, College of Medicine, University of South Florida, Tampa, Florida 33612

View Article
October 2014

Lysophosphatidic acid acyltransferase beta regulates mTOR signaling.

PLoS One 2013 31;8(10):e78632. Epub 2013 Oct 31.

Department of Experimental Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America.

View Article
August 2014

Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.

Oncotarget 2014 May;5(10):2947-61

Drug Discovery Department, Chemical Biology and Molecular Medicine Program, Chemical Biology Core Moffitt Cancer Center and Research Institute.

View Article
May 2014

GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells.

ACS Chem Biol 2014 Feb 20;9(2):353-8. Epub 2013 Nov 20.

Department of Drug Discovery, ‡Department of Thoracic Oncology, and §Molecular Oncology and Proteomics, H. Lee Moffitt Cancer Center & Research Institute , Tampa, Florida 33612-9497, United States.

View Article
February 2014

Development of new -Arylbenzamides as STAT3 Dimerization Inhibitors.

Medchemcomm 2013 Jun;4(6):932-941

Departments of Drug Discovery, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA.

View Article
June 2013

Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors.

J Med Chem 2013 May 13;56(10):3783-805. Epub 2013 May 13.

Drug Discovery Department, Moffitt Cancer Center , 12902 Magnolia Drive, Tampa, Florida 33612, USA.

View Article
May 2013

A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation.

Cancer Res 2013 Mar 15;73(6):1922-33. Epub 2013 Jan 15.

Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

View Article
March 2013

Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2.

Cancer Lett 2012 Jul 1;320(1):81-5. Epub 2012 Feb 1.

Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States.

View Article
July 2012

A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A.

ACS Chem Biol 2012 Apr 27;7(4):698-706. Epub 2012 Jan 27.

Drug Discovery Department, Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, United States.

View Article
April 2012

Ack1 tyrosine kinase activation correlates with pancreatic cancer progression.

Am J Pathol 2012 Apr 7;180(4):1386-93. Epub 2012 Feb 7.

Department of Drug Discovery, Moffitt Cancer Center, Tampa, Florida 33612, USA.

View Article
April 2012

Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors.

J Med Chem 2012 Mar 14;55(5):1978-98. Epub 2012 Feb 14.

Drug Discovery Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, Florida 33612, USA.

View Article
March 2012

Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs.

Bioorg Med Chem Lett 2011 Jan 4;21(2):730-3. Epub 2010 Dec 4.

Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.

View Article
January 2011

Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.

Biochem Pharmacol 2010 Sep 25;80(6):801-10. Epub 2010 May 25.

Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, United States.

View Article
September 2010

Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors.

Bioorg Med Chem 2010 Aug 18;18(15):5576-92. Epub 2010 Jun 18.

Drug Discovery Department, Moffitt Cancer Center, 12901 Magnolia Drive, Tampa, FL 33612, USA.

View Article
August 2010

Targeting protein tyrosine phosphatases for anticancer drug discovery.

Curr Pharm Des 2010 Jun;16(16):1843-62

Departments of Molecular Oncology and Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL 33612, USA.

View Article
June 2010

Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.

Bioorg Med Chem 2008 Apr 7;16(8):4438-56. Epub 2008 Mar 7.

Medicinal Chemistry, Department of Pharmacy and Pharmacology and Sterix Ltd, University of Bath, Claverton Down BA2 7AY, UK.

View Article
April 2008

Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.

Mol Pharmacol 2006 Aug 22;70(2):562-70. Epub 2006 May 22.

Molecular Oncology Program, SRB-3, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.

View Article
August 2006

Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.

ChemMedChem 2006 Apr;1(4):464-81

Medicinal Chemistry, Department of Pharmacy and Pharmacology and Sterix Ltd., University of Bath, Claverton Down, Bath, and St. Mary's Hospital, London, UK.

View Article
April 2006

17Beta-hydroxysteroid dehydrogenase Type 1 and Type 2: association between mRNA expression and activity in cell lines.

Mol Cell Endocrinol 2006 Mar 21;248(1-2):246-9. Epub 2006 Feb 21.

Endocrinology and Metabolic Medicine and Sterix Ltd., Imperial College, St. Mary's Hospital, London W2 1NY, UK.

View Article
March 2006

Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.

J Med Chem 2005 Apr;48(8):2759-62

Medicinal Chemistry, Department of Pharmacy and Pharmacology and Sterix Ltd., University of Bath, Claverton Down, Bath, BA2 7AY, U.K.

View Article
April 2005